The addressable market has been there for years. Adherium's product technology has been proven to enhance adherence, following various clinical trials and studies. Now, it has the FDA 501(k) clearance for the next generation Hailie sensor, plus a decently sized war-chest to execute with. All good things going for the company.
However, Adherium has had numerous FDA 501(k) clearances for product within its range previously, with the first of these stretching back to 2017. The link that has been suggested that FDA clearance = $$ is not accurate. As many long-term holders will know, the obstacle has been commercialisation of the products. Can Rick Legleiter break new ground in this area, like his incumbents (including the company founder) have not managed to do?
I hope that this is a turning point, but we will see. At this point, I remain cynical.
Interested to hear what other long-suffering holders may think - @jamwolf etc.
ADR Price at posting:
2.2¢ Sentiment: None Disclosure: Held
